Avid Bioservices Inc (CDMO)

[biopharm]

Furthermore, the discovery that PS itself stimulates an immunosuppressive GPCR namely GPR174 on all lymphocytes represents a significant advancement in our understanding of how PS regulates tumor immunity.
...
..

“Our team’s discovery of the GPR174-controlled cancer-immunity pathways and their interrelationships with the adenosine pathway have been methodically elucidated and defined,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer. “Simply put, Omeros has discovered that there are two feet on the cAMP brake pedal restraining immunity against the tumor and, to enable effective tumor-killing activity, both GPR174 and the adenosine pathway must be inhibited. We are optimizing our small-molecule GPR174 inhibitors with the objective of moving orally available therapeutics into the clinic as rapidly as possible. We look forward to providing physicians and patients with a new and broadly applicable option in cancer immunotherapy.”

Omeros is preparing a manuscript for publication detailing its GPR174-related discoveries and data and plans to present these same discoveries and data beginning this year at upcoming oncology international congresses.

Omeros is establishing an expansive and exclusive intellectual property position directed to GPR174 inhibitors as well as to inhibition of the GPR174 receptor, both alone and in combination with other cancer therapies, for the treatment of any tumor or malignancy.

______

As many are becoming familiar with G-protein coupled receptors .... others will PROVE that patents created AFTER PS Targeting ....and trying to say a patent is going after the downstreamers, will face the facts that going after flipped PS ...is what is changing the protein pathways

"Our goals are to understand how G-protein-coupled receptors (GPCR) transduce signals to downstream effectors in immune cells,..."

Looks like Omeros and Dr John H Kehrl are on the same PS Targeting paths ....
______

An Integrin/MFG-E8 shuttle loads HIV-1 viral like particles onto follicular dendritic cells in mouse lymph node

Publication history
Received: April 17, 2019
Accepted: November 8, 2019
Accepted Manuscript published:
December 3, 2019 (version 1)

Author details
Chung Park
B-cell Molecular Immunology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, Bethesda, United States
Competing interests The authors declare that no competing interests exist.

John H Kehrl
B-cell Molecular Immunology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, Bethesda, United States

....
....

Using a phosphatidylserine binding domain and an RGD motif, MFG-E8 helps target HIV-1 VLPs to av integrin bearing SMs. Lack of MFG-E8 or integrin blockade severely limits HIV-1 VLP spread onto FDC networks. Direct SM-FDC virion transfer also depends upon short-lived FDC network abutment, likely triggered by SCSM antigen uptake. This provides a mechanism for rapid FDC loading broadening the opportunity for rare, antigen reactive follicular B cells to acquire antigen, and a means for HIV virions to accumulate on the FDC network.
....
....


https://elifesciences.org/articles/47776

____

GPR174, an orphan G protein-coupled receptor (GPCR) narrowly expressed in immune cells and linked to cancers, substantially and statistically significantly ...

https://investor.omeros.com/news-releases/news-release-details/omeros-proprietary-orphan-gpcr-program-delivers-new-target-and

________

John H. Kehrl, M.D.
Senior Investigator
B-Cell Molecular Immunology Section

Extracellular signals modulate and regulate the function of cells that participate in immune responses. Some of these signals activate pathways that utilize heterotrimeric G proteins to transduce signals. The importance of chemokine receptor signaling in the orchestration and coordination of immune cell trafficking is but one example of the importance of heterotrimeric G-protein-mediated signaling in immune function. Our goals are to understand how G-protein-coupled receptors (GPCR) transduce signals to downstream effectors in immune cells,
...
...

https://irp.nih.gov/pi/john-kehrl

_____

Diana Aronin

Manager, Global Regulatory Affairs Development, Oncology at Takeda
TakedaBoston University School of Public Health

Waltham, Massachusetts
456 connections
....
....

I say Takeda should just jump over Roche and go public with their PS Targeting efforts, since Takeda just bought Shire and now the MA #1 employer ....Aronin is right in Waltham ...ever so close to CEO Laura Benjamin and wow....even a DIRECT connection to Lana Gladstein : ) that is close with Avid BOD Mark Bamforth....